OakChart

Rigel Pharmaceuticals

RIGLHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:09 PM ET

44.14+0.23 (0.52%)
2026-11-11 21:10 CET
Market cap
826.83 USD m
Revenue, TTM
288.21 USD m
Net income, TTM
307.19 USD m
Free cash flow, TTM
89.93 USD m
EPS diluted, TTM
15.51
P/E
2.85
Compare

Price

RIGL against its 20, 50 and 200-day averages
2050200beatmiss
30.0040.0050.00615K1.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RIGLclose 44.1420-day 47.7050-day 47.59200-day 37.4944.1452w high52w low

16.1% under the 52-week high of 52.61 on 30 Oct 2026. 52-week low 24.95 on 19 Mar 2026. Last 15 sessions, 39.9% high to low

Volume 0.35× normal · the line is the 50-bar volume average

Profile

RIGL
52-week range, 69% of the way up
24.9552.60

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

IndexRUT
Employees174
IPONov 29, 2000
Beta1.26
ATR, 14d2.53
Rel volume0.35
Short float13.93%
Insider own3.32%
Inst own89.45%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap831.15M
Enterprise Value739.63M
Income307.19M
Sales288.21M
Book/sh23.70
Cash/sh5.27
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees174
IPONov 29, 2000

Ratios

P/E2.85
Forward P/E9.92
PEG-
P/S2.88
P/B1.86
P/C8.37
P/FCF9.24
EV/EBITDA9.30
EV/Sales2.57
Quick Ratio2.19
Current Ratio2.39
Debt/Eq0.02
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)15.51
EPS next Y4.45
EPS next Q1.05
EPS this Y-83.23%
EPS next Y36.23%
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y34.76% 22.06%
EPS Y/Y TTM165.65%
Sales Y/Y TTM2.18%
EPS Q/Q-55.71%
Sales Q/Q16.45%
EarningsNov 05 AMC
EPS/Sales Surpr.-23.78% 1.12%

Ownership

Insider Own3.32%
Insider Trans-0.79%
Inst Own89.45%
Inst Trans-7.15%
ROA80.16%
ROE109.18%
ROIC69.02%
Gross Margin89.64%
Oper. Margin26.28%
Profit Margin106.59%
SMA20-7.47%
SMA50-7.25%
SMA20017.75%
Trades-

Technical

Shs Outstand18.78M
Shs Float18.20M
Short Float13.93%
Short Ratio9.74
Short Interest2.54M
52W High52.60 -16.09%
52W Low24.95 76.91%
Volatility8.51% 4.78%
ATR (14)2.53
RSI (14)42.84
Beta1.26
Rel Volume0.35
Avg Volume260.31K
Volume78,896

Performance

Perf Week-13.94%
Perf Month-6.36%
Perf Quarter8.21%
Perf Half Y37.38%
Perf YTD3.06%
Perf Year16.31%
Perf 3Y439.67%
Perf 5Y38.37%
Perf 10Y37.94%
Recom1.80
Target Price64.40
Prev Close43.91
Price44.14
Change %0.52%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Nov 05, 2025UpgradeJJefferiesHold → Buy$42-4.8%
Apr 03, 2023ResumedPPiper SandlerNeutral$2-95.5%
Jun 09, 2022DowngradeCCitigroupBuy → Neutral
Jun 08, 2022DowngradePPiper SandlerOverweight → Neutral$7 → $1-97.7%
Jun 08, 2022DowngradeCCantor FitzgeraldOverweight → Neutral$6 → $1-97.7%
Mar 23, 2022InitiatedRB. Riley SecuritiesNeutral$4-90.9%
Nov 09, 2020DowngradeJJP MorganOverweight → Neutral
Nov 15, 2019ResumedCCantor FitzgeraldOverweight$7 → $5-88.7%
Sep 26, 2019ResumedJJP MorganOverweight$7-84.1%
Mar 01, 2019ReiteratedCCantor FitzgeraldOverweight$9 → $7-84.1%

Peers

Mkt cap
TickerCompanyMkt cap
SNDXSyndax Pharmaceuticals Inc872.32M
AGIOAgios Pharmaceuticals Inc1.96B
GERNGeron Corp641.08M
KURAKura Oncology Inc695.23M
AAPGAscentage Pharma Group International ADR1.42B
VSTMVerastem Inc1.14B
INCYIncyte Corp24.90B
SNYSanofi ADR115.15B
DMRADamora Therapeutics Inc1.46B
ARGXArgen X SE ADR61.26B

Insider trading

11 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Schorno Dean LEVP & Chief Financial OfficerSep 02 '26Option Exercise21.724,60099,92982,962Sep 03 07:02 PM
Ali-Jackson KamilDirectorJun 22 '26Sale35.002,50087,50010,125Jun 24 04:04 PM
Ali-Jackson KamilDirectorJun 22 '26Proposed Sale35.002,50087,500Jun 22 03:12 PM
Schorno Dean LEVP & Chief Financial OfficerJun 01 '26Option Exercise14.833,38150,13979,718Jun 03 06:03 PM
Ali-Jackson KamilDirectorMay 26 '26Sale29.172,50072,92512,625May 28 04:19 PM
Ali-Jackson KamilDirectorMay 26 '26Proposed Sale29.172,50072,925May 26 10:43 AM
MOOS WALTER HDirectorFeb 20 '26Option Exercise24.004,00096,00016,722Feb 24 04:58 PM
MOOS WALTER HDirectorFeb 20 '26Sale36.364,000145,44012,722Feb 24 04:58 PM
MOOS WALTER HDirectorFeb 20 '26Proposed Sale36.364,000145,440Feb 20 01:52 PM
RODRIGUEZ RAUL RCEO, PresidentJan 26 '26Option Exercise27.4080,0002,192,000285,243Feb 04 04:20 PM
Schorno Dean LEVP & Chief Financial OfficerDec 22 '25Option Exercise21.516,500139,78664,235Dec 29 08:06 PM

Held by

AUM
TickerCompanyAUM
AVUVAvantis U.S. Small Cap Value ETFAUM: 32.39B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
BSVOEA Bridgeway Omni Small-Cap Value ETFAUM: 2.44B

News

latest 14 of 200
  • Rigel to Present at the Jefferies Global Healthcare Conference in London (PR Newswire)
  • Rigel Misses On EPS As VEPPANU Launch Spending Compresses Margins, While TAVALISSE Slowdown Clouds A Strong Debut (Earnings Whispers) -10.88% -13.26%
  • Rigel: Q3 Earnings Snapshot (Associated Press)
  • Rigel Reports Third Quarter 2026 Financial Results (PR Newswire)
  • Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition (PR Newswire)
  • Rigel's First Vepinu Quarter Tests Whether Its Breast Cancer Bet Can Offset Slowing Base Sales (Earnings Whispers)
  • Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results (PR Newswire)
  • Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026 (PR Newswire)
  • Big Pharma Is Pouring Billions Into a New Class of 'Protein Degrader' Drugs (The Wall Street Journal)
  • Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
  • Rigel to Participate in Upcoming September Investor Conferences (PR Newswire)
  • Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers (BioPharma Dive)
  • Rigel Announces Availability of VEPPANU (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer (PR Newswire)
  • Rigel: Q2 Earnings Snapshot (Associated Press)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-050.6500.8530.65080.8980.005
2026Q22026-08-040.8800.0880.88478.7055.275
2026Q12026-05-050.4400.7950.44058.8262.405
2025Q42026-03-0313.5401.20213.54369.8068.705
2025Q32025-11-041.4600.9001.45769.4661.885
2025Q22025-08-053.2802.5803.282101.6988.953
2025Q12025-05-060.6300.0890.63053.3343.875
2024Q42025-03-040.8000.4510.79757.6050.106
2024Q32024-11-070.7000.0590.70455.3141.946
2024Q22024-08-06-0.060-0.292-0.05936.8433.425
2024Q12024-05-07-0.500-0.288-0.47129.5331.476
2023Q42024-03-050.000-0.2040.04235.7934.106
2023Q32023-11-07-0.300-0.710-0.32628.1327.206
2023Q22023-08-01-0.400-0.780-0.38026.8925.706
2023Q12023-05-02-0.800-0.958-0.78026.0724.076
2022Q42023-03-070.100-0.9470.08151.2836.527

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-4.000-3.778-3.99659.2959.57
2020FY-1.800-1.724-1.763108.62108.56
2021FY-1.100-1.023-1.051149.24150.63
2022FY-3.400-4.531-3.397120.2497.78
2023FY-1.400-1.701-1.442116.88114.73
2024FY0.9900.3890.989179.28171.8
2025FY19.4806.63819.480294.28293.19
2026FY-3.267--306.34
2027FY-4.451--374.42
2028FY-5.868--448.73
2029FY-4.965--504.71
2030FY-6.030--571.11

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0653189.0881.4193.31
2026Q4S2026-11-0550088.1281.4197.59
2026Q4S2026-11-0351089.5981.4197.59
2026Q4S2026-10-2850088.1281.4197.59
2026Q4S2026-10-2750188.1281.4197.59
2026Q4S2026-10-1951188.1281.4197.59
2026Q4S2026-10-1652288.1281.4197.59
2026Q4S2026-10-0652288.1281.4197.62
2026Q4S2026-08-1453288.1281.4197.62
2026Q4S2026-08-1353188.2982.2797.62
2026Q4S2026-08-0553187.0678.2297.62
2026Q4S2026-07-2652085.5573.8597.60
2026Q4S2026-07-2452185.5573.8597.60
2026Q4S2026-07-2352185.5573.8597.60

Estimate history

EPS, annual-6.2-4.391-3.996-1.763-1.051-3.397-1.4420.98919.48115.5109
Period201720182019202020212022202320242025TTM
EPS, quarterly0.7040.7970.633.2821.45713.5430.440.8840.645
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual4.48444.50959.288108.621149.236120.242116.882179.278294.282288.21
Period201720182019202020212022202320242025TTM
Sales, quarterly55.30757.59653.333101.68569.46269.80258.81878.70380.89
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual14.68116.71716.79916.93217.1617.3417.48317.7118.31118.783
Period201720182019202020212022202320242025MRQ
Shares, quarterly17.61317.7117.86717.93718.14418.31118.48218.65418.783
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue288.21294.28179.28116.88120.24149.24108.6259.2944.51
Cost of Goods Sold Incl. D&A29.8719.6218.657.111.751.660.900.910.88
Gross Profit258.34274.66160.63109.77118.49147.57107.7358.3843.63
Selling, General and Administrative Excl. Other182.61149.19136.44130.26173.28156.55136.70127.47116.31
Research and Development54.5933.3023.3824.5260.2765.2460.1052.8846.90
Other Operating Expense0.000.000.000.00-0.560.000.000.000.00
Operating Income75.73125.4724.19-20.49-54.23-8.97-28.97-69.09-72.68
Interest Expense3.967.327.926.873.714.861.350.340.00
Unusual Expense0.210.000.000.001.323.520.00-0.00
Net Income Before Taxes75.36121.8318.37-25.09-58.57-17.31-29.74-66.89-70.48
Income Taxes-231.83-245.200.880.000.000.600.000.000.00
Consolidated Net Income307.19367.0217.48-25.09-58.57-17.91-29.74-66.89-70.48
Net Income From Continuing Operations307.19367.0217.48-25.09-58.57-17.91-29.74-66.89-70.48
Net Income307.19367.0217.48-25.09-58.57-17.91-29.74-66.89-70.48
EPS (Recurring)15.0419.480.99-1.44-3.34-0.91-1.76-4.00-4.39
EPS (Basic, Before Extraordinaries)16.8320.410.99-1.44-3.40-1.05-1.76-4.00-4.39
EPS (Diluted)15.5119.480.99-1.44-3.40-1.05-1.76-4.00-4.39
EBITDA79.57127.8826.42-19.25-53.23-7.81-28.27-68.41-72.09
Non-Operating Income (Expense)3.803.682.092.270.680.050.582.532.20
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense14.1410.049.798.8112.386.927.299.127.70
Price To Earnings Ratio2.832.8377.65------
Price To Sales Ratio3.412.741.662.162.153.035.446.048.30
Gross Margin89.6493.3389.6093.9298.5598.8899.1898.4798.02
Operating Margin26.2842.6313.49-17.53-45.10-6.01-26.67-116.53-163.30
Net Margin106.59124.729.75-21.47-48.71-12.00-27.38-112.83-158.35
Shares Outstanding18.7818.3117.7117.4817.3417.1616.9316.8016.72
Market Capitalization826.83826.83296.28252.83259.25454.75592.61359.49384.49

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue80.8978.7058.8269.8069.46101.6953.3357.60
Cost of Goods Sold Incl. D&A10.788.534.615.964.754.504.415.79
Gross Profit70.1170.1854.2163.8564.7197.1848.9251.81
Selling, General and Administrative Excl. Other53.0046.6042.3340.6836.2936.0836.1535.15
Research and Development18.2713.9611.6810.697.356.828.445.63
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income17.1123.5711.8823.1728.4261.1012.7716.66
Interest Expense0.260.571.431.701.891.871.851.96
Unusual Expense0.000.210.000.000.000.000.000.00
Net Income Before Taxes17.4123.5911.6622.7127.6259.9811.5115.22
Income Taxes4.226.293.00-245.35-0.280.370.070.88
Consolidated Net Income13.1917.298.65268.0627.9059.6111.4514.34
Net Income From Continuing Operations13.1917.298.65268.0627.9059.6111.4514.34
Net Income13.1917.298.65268.0627.9059.6111.4514.34
EPS (Recurring)0.650.890.4413.541.463.280.630.80
EPS (Basic, Before Extraordinaries)0.700.930.4714.721.553.330.640.81
EPS (Diluted)0.650.880.4413.541.463.280.630.80
EBITDA18.9024.4212.4823.7729.0261.7113.3817.26
Non-Operating Income (Expense)0.560.791.211.241.090.750.590.52
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.835.412.732.172.662.592.631.65
Price To Earnings Ratio2.832.091.436.955.239.0418.5177.65
Price To Sales Ratio3.412.771.782.881.921.271.611.69
Gross Margin86.6789.1792.1791.4793.1695.5791.7389.95
Operating Margin21.1529.9520.2133.1940.9160.0923.9528.92
Net Margin16.3021.9714.71384.0440.1758.6321.4624.90
Shares Outstanding18.7818.6518.4818.3118.1417.9417.8717.71
Market Capitalization826.83723.80499.51777.42508.16334.75321.36296.28

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments154.9677.3256.9358.21124.9757.3398.08128.54115.75
Short Term Receivables51.7641.6230.5540.3215.4715.9710.114.080.00
Inventories11.519.805.529.926.625.641.350.890.00
Other Current Assets21.946.376.267.467.4110.049.463.481.68
Total Current Assets240.17135.1099.27115.90154.4788.98119.00136.99117.43
Net Property, Plant & Equipment0.950.341.032.7911.8920.5727.871.390.88
Total Investments and Advances0.060.000.000.000.000.000.000.000.00
Intangible Assets24.7527.1013.8814.95-----
Deferred Tax Assets292.88329.23-------
Other Assets1.821.443.060.640.970.820.700.730.80
Total Assets560.62493.21117.22134.28167.33110.38147.57139.11119.11
Short Term Debt Incl. Current Port. of LT Debt30.437.567.921.139.898.627.270.000.00
Accounts Payable7.193.347.1422.513.793.714.156.392.64
Other Current Liabilities61.6252.4038.2041.5749.8728.5146.7921.3415.70
Total Current Liabilities99.2463.3053.2765.2163.5540.8458.2127.7318.34
Long Term Debt22.8852.4152.6640.4220.6730.4729.040.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities47.02329.23-------
Other Liabilities0.0044.9839.9442.2652.735.046.501.500.13
Total Liabilities169.14489.92145.87147.90136.9576.3593.7529.2318.46
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity391.483.29-28.64-13.6230.3734.0353.81109.88100.65
Total Shareholders Equity391.483.29-28.64-13.6230.3734.0353.81109.88100.65
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity391.483.29-28.64-13.6230.3734.0353.81109.88100.65
Total Liabilities & Stockholders Equity560.62493.21117.22134.28167.33110.38147.57139.11119.11
Book Value Per Share21.380.19-1.64-0.791.772.013.206.576.86
Tangible Book Value Per Share20.03-1.34-2.43-1.651.772.013.206.576.86
Full-Time Employees174164147155165169163158103
Price to Book Ratio1.85-20.24-7.94-13.0714.9717.426.683.5010.12
Return on Assets69.665.73-19.95-38.84-12.90-23.06-46.67-54.59-79.08
Return on Equity185.94---699.05-55.63-67.72-81.73-66.96-100.20
Return on Invested Capital88.5831.39-104.48-218.52-35.09-46.12-80.74-64.14-77.49
Quick Ratio2.301.981.761.632.332.042.024.916.40
Current Ratio2.422.131.861.782.432.182.044.946.40

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income307.19367.0217.48-25.09-58.57-17.91-29.74-66.89-70.48
Depreciation3.842.422.231.241.001.160.710.680.59
Other Funds (Non Cash)17.63-28.4211.618.5912.8712.917.178.046.94
Funds from Operations94.1395.1731.32-15.26-44.71-3.84-21.86-58.17-62.95
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-4.21-19.510.159.52-29.059.72-30.3216.664.12
Cash from Operating Activities89.9275.6631.47-5.74-73.765.88-52.19-41.51-58.83
Capital Expenditures-70.550.00-0.40-15.00-0.45-0.63-1.26-1.46-1.11
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.100.260.890.000.000.000.00
Purchase or Sale of Investments36.22-92.364.4310.4472.33-79.4148.73-22.2026.07
Purchase of Investments-93.96-153.49-35.27-31.21-28.89-141.46-81.71-145.33-78.00
Sale Or Maturity of Investments130.1861.1339.7041.65101.2362.05130.43123.13104.07
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-34.33-92.364.13-4.3072.78-80.0447.47-23.6624.96
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock2.628.101.961.052.124.782.601.5871.89
Repurchase of Common Pref Stock-5.280.000.000.000.000.000.000.000.00
Sale of Common Pref Stock7.898.101.961.052.124.782.601.5871.89
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.0067.16
Issuance or Reduction of Debt, Net-55.09-7.50-3.6017.324.4357.909.979.790.00
Change in Long Term Debt-55.09-7.50-3.6017.324.4357.909.979.790.00
Issuance of Long Term Debt39.660.000.0019.9519.5457.909.979.790.00
Reduction of Long Term Debt-94.75-7.50-3.60-2.63-15.120.000.000.000.00
Net Financing Active Other Cash Flow-5.000.00-10.000.000.000.000.000.000.00
Other Financing Activities Uses-5.000.00-10.000.000.000.000.000.000.00
Cash from Financing Activities-57.480.60-11.6418.376.5562.6712.5711.3771.89
Net Change in Cash-1.89-16.1123.968.335.57-11.487.85-53.8038.03
Free Cash Flow89.9375.6631.43-5.74-74.215.25-53.45-42.97-59.93
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow10.9410.679.46--86.04---
Deferred Taxes & Investment Tax Credit--245.850.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments99.3195.33146.68154.96137.14108.38
Short Term Receivables56.4656.0450.9551.7645.9239.91
Inventories15.8014.3711.6511.5113.3010.42
Other Current Assets16.9619.7924.7521.9418.5616.68
Total Current Assets188.52185.53234.03240.17214.93175.39
Net Property, Plant & Equipment0.500.650.790.951.101.24
Total Investments and Advances0.060.060.060.060.000.00
Intangible Assets94.5993.8824.1624.7525.3425.92
Deferred Tax Assets234.53238.07243.28292.88--
Other Assets5.682.892.301.821.174.18
Total Assets523.88521.07504.61560.62242.53206.74
Short Term Debt Incl. Current Port. of LT Debt7.7939.8930.5030.4330.3622.88
Accounts Payable11.443.914.497.193.857.29
Other Current Liabilities59.5451.7854.5161.6260.2056.47
Total Current Liabilities78.7795.5989.4999.2494.4086.64
Long Term Debt0.000.0615.2222.8830.5238.17
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---47.02--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities78.7795.64104.71169.14124.92124.80
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity445.11425.42399.90391.48117.6181.93
Total Shareholders Equity445.11425.42399.90391.48117.6181.93
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity445.11425.42399.90391.48117.6181.93
Total Liabilities & Stockholders Equity523.88521.07504.61560.62242.53206.74
Book Value Per Share23.7022.8121.6421.386.484.57
Tangible Book Value Per Share18.6617.7720.3320.035.093.12
Full-Time Employees---174--
Price to Book Ratio1.851.811.266.616.2018.02
Return on Assets80.1688.46107.0469.6659.3358.38
Return on Equity109.18126.90174.08185.94220.06376.09
Return on Invested Capital2.964.062.0864.6918.8349.64
Quick Ratio2.191.792.482.302.141.90
Current Ratio2.391.942.622.422.282.02

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income13.1917.298.65268.0627.9059.61
Depreciation1.790.850.600.600.600.61
Other Funds (Non Cash)4.827.023.292.502.90-36.95
Funds from Operations23.3430.3715.1125.3231.4023.27
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital11.230.29-12.38-3.34-7.377.27
Cash from Operating Activities34.5630.652.7321.9824.0330.54
Capital Expenditures-0.22-70.350.000.01-0.010.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-18.2387.80-7.97-25.37-33.16-23.28
Purchase of Investments-26.13-4.98-23.92-38.92-53.89-39.03
Sale Or Maturity of Investments7.9092.7815.9513.5520.7315.75
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-18.4517.45-7.97-25.36-33.17-23.28
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.751.35-3.422.934.270.42
Repurchase of Common Pref Stock-1.02-0.51-3.740.000.000.00
Sale of Common Pref Stock2.781.860.322.934.270.42
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-32.04-8.05-7.50-7.500.000.00
Change in Long Term Debt-32.04-8.05-7.50-7.500.000.00
Issuance of Long Term Debt-0.0439.700.000.000.000.00
Reduction of Long Term Debt-32.00-47.75-7.50-7.500.000.00
Net Financing Active Other Cash Flow0.00-5.000.000.000.000.00
Other Financing Activities Uses0.00-5.000.000.000.000.00
Cash from Financing Activities-30.29-11.70-10.92-4.574.270.42
Net Change in Cash-14.1736.41-16.17-7.95-4.877.68
Free Cash Flow34.5630.652.7321.9924.0230.54
Price to Free Cash Flow10.949.646.7111.217.965.17

Revenue breakdown

DevelopmentMilestones2025: 3.00M
Discounts and allowances2024: -65.02M 2025: -77.98M
Government Contract2025: 265.00K
GrossProduct2024: 209.92M 2025: 309.96M
License2024: 14.00M
Release Of Share Cost Liability2025: 39.98M
RoyaltyDeliveryOfDrugSuppliesAndOthers2024: 20.38M 2025: 19.05M
United States2024: 179.28M 2025: 294.28M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.93%2.5M18.2M258.60K
2026-10-1515.13%2.7M18.1M276.98K
2026-09-3015.81%2.9M18.1M307.82K
2026-09-1517.67%3.2M18.1M339.79K
2026-08-3117.63%3.2M18.1M356.32K
2026-08-1417.76%3.2M18.0M355.66K
2026-07-3117.14%3.1M18.0M388.44K
2026-07-1517.67%3.2M17.9M395.67K
2026-06-3018.18%3.3M17.9M387.36K
2026-06-1519.33%3.5M17.9M361.02K
2026-05-2922.01%3.9M17.9M396.75K
2026-05-1522.07%3.9M17.9M394.54K
2026-04-3021.95%3.9M17.9M349.19K
2026-04-1523.01%4.1M17.9M346.84K
2026-03-3121.30%3.8M17.9M376.96K
2026-03-1320.85%3.7M17.9M436.17K
2026-02-2720.98%3.8M17.9M436.03K
2026-02-1321.58%3.8M17.6M494.91K
2026-01-3021.09%3.7M17.7M593.99K
2026-01-1520.94%3.7M17.7M602.34K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call30.0012.0016.5020.773.25612.000.000.837-0.3370.017
call35.007.0011.505.552.33661.000.000.783-0.2990.020
call38.004.108.500.001.8510.000.000.736-0.2670.023
call39.003.007.800.001.9050.000.000.711-0.2510.023
call40.002.506.902.201.80117.000.000.686-0.2360.024
call41.002.356.002.501.5711.000.000.668-0.2250.025
call42.001.904.901.301.3692.000.000.636-0.2060.026
call43.000.703.400.000.9990.000.000.598-0.1880.027
call44.000.403.200.971.1431.000.000.543-0.1790.027
call45.000.852.751.641.12240.003.000.509-0.2090.028
call46.000.352.306.721.0991.000.000.456-0.1860.027
call47.000.352.004.301.1419.000.000.405-0.1820.027
call48.000.004.905.151.23013.000.000.377-0.1840.026
call49.000.001.605.181.1913.000.000.327-0.1680.025
call50.000.150.550.260.8191353.000.188-0.0870.019
call55.000.001.150.051.18961.000.000.142-0.1040.016
call60.000.000.951.101.50047.000.000.119-0.1160.014
call65.000.004.900.351.7681460.000.105-0.1250.013
call70.000.004.900.182.0509.000.000.101-0.1400.012
put30.000.004.900.003.5010.000.00-0.163-0.3330.017
put35.000.004.900.602.5904.000.00-0.217-0.2930.020
put38.000.004.901.402.07917.000.00-0.264-0.2620.023
put39.000.004.901.401.8935.000.00-0.287-0.2470.023
put40.000.004.902.191.7243.000.00-0.310-0.2330.024
put41.000.004.901.581.5559.000.00-0.338-0.2210.025
put42.000.252.751.851.4083.000.00-0.364-0.2020.026
put43.000.304.101.501.3644.000.00-0.403-0.1830.027
put44.000.203.102.551.1821.000.00-0.450-0.1740.027
put45.001.004.904.301.6368.000.00-0.489-0.2040.028
put46.001.204.900.001.4220.000.00-0.544-0.1810.027
put47.001.505.808.241.4980.000.00-0.594-0.1770.027
put48.003.305.907.901.30515.000.00-0.625-0.1800.026
put49.003.007.500.001.6530.000.00-0.674-0.1630.025
put50.004.008.005.501.57610.000.00-0.812-0.0810.019
put55.009.0013.0013.611.9901.000.00-0.859-0.0980.015
put60.0013.5018.000.002.3520.000.00-0.882-0.1100.014
put65.0018.5023.000.002.6770.000.00-0.895-0.1180.013
put70.0023.5028.000.003.0040.000.00-0.904-0.1250.012

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-04S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-048-KCurrent report2026-08-04SEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-018-KCurrent report2026-06-25SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-22144Filing for proposed sale of securities under Rule 144.SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-178-KCurrent report2026-06-11SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-05-284Statement of changes in beneficial ownership of securities2026-05-26SEC
2026-05-26144Filing for proposed sale of securities under Rule 144.SEC
2026-05-208-KCurrent report2026-05-14SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060087.50K1
2026-050072.93K1
2026-040000
2026-030000
2026-0200145.44K1
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.10.48%
Soleus Capital Management, L.P.9.96%
ARMISTICE CAPITAL, LLC9.04%
STATE STREET CORP5.62%
VANGUARD CAPITAL MANAGEMENT LLC4.24%
LSV ASSET MANAGEMENT4.22%
AMERICAN CENTURY COMPANIES INC4.01%
D. E. Shaw & Co., Inc.2.93%
Assenagon Asset Management S.A.2.87%
GEODE CAPITAL MANAGEMENT, LLC2.59%

Funds

Fund% owned
Avantis U.S. Small Cap Value ETF4.20%
Nomura Healthcare Fund0.86%
BlackRock Advantage Small Cap Core Fund0.59%
Burney U.S. Factor Rotation ETF0.47%
Pacer US Small Cap Cash Cows 100 ETF0.46%
EA Bridgeway Omni Small-Cap Value ETF0.43%
First Trust Dow Jones Select MicroCap Index Fund0.33%
Avantis U.S. Small Cap Value Fund0.32%
Omni Small-Cap Value Fund0.24%
Virtus Biotech Etf0.22%

OakChart. RIGL. Cached 15 minutes.